Ii-Key/HER-2/neu MHC class-II antigenic epitope vaccine peptide for breast cancer

Author： Gillogly Michael   Kallinteris Nikoletta   Xu Minzhen   Gulfo Joseph   Humphreys Robert   Murray James  

Publisher： Springer Publishing Company

ISSN： 0340-7004

Source： Cancer Immunology, Immunotherapy, Vol.53, Iss.6, 2004-06, pp. : 490-496

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Ii-Key/HER-2/neu(776–790) hybrid peptides induce more effective immunological responses over the native peptide in lymphocyte cultures from patients with HER-2/neu+ tumors

By Sotiriadou Nectaria   Kallinteris Nikoletta   Gritzapis Angelos   Voutsas Ioannis   Papamichail Michael   Hofe Eric   Humphreys Robert   Pavlis Theodoros   Perez Sonia   Baxevanis Constantin  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 5, 2007-05 ,pp. : 601-613

Springer Publishing Company

Access to resources Recommend Favorite

Analysis of naïve and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine

By Hueman Matthew   Stojadinovic Alexander   Storrer Catherine   Dehqanzada Zia   Gurney Jennifer   Shriver Craig   Ponniah Sathibalan   Peoples George  

Cancer Immunology, Immunotherapy, Vol. 56, Iss. 2, 2007-02 ,pp. : 135-146

Springer Publishing Company

Access to resources Recommend Favorite

Her-2/neu as Predictive Marker for Endocrine Therapy and Chemotherapy in Patients with Metastatic Breast Cancer

By Köstler Wolfgang J.   Zielinski Christoph C.  

Breast Cancer Research and Treatment, Vol. 81, Iss. 1, 2003-01 ,pp. : 73-84

Springer Publishing Company

Access to resources Recommend Favorite

HER-2/Neu overexpression does not predict response to neoadjuvant chemotherapy or prognosticate survival in patients with locally advanced breast cancer

By Tulbah Asma   Ibrahim Ezzeldin   Ezzat Adnan   Ajarim Dahish   Rahal Mohammed   Weshi Amr   Sorbris Ralph  

Medical Oncology, Vol. 19, Iss. 1, 2002-03 ,pp. : 15-23

Humana Press, Inc

Access to resources Recommend Favorite

HER-2/neu status and response to CMF: retrospective study in a series of operable breast cancer treated with primary CMF chemotherapy

By Falo Catalina   Moreno Abelardo   Varela Mar   Lloveras Belen   Figueras Agnès   Escobedo Agustín  

Journal of Cancer Research and Clinical Oncology, Vol. 133, Iss. 7, 2007-07 ,pp. : 423-429

Springer Publishing Company

Access to resources Recommend Favorite